Form 4: DiaMedica Therapeutics Director Acquires Stock Options, Increases Beneficial Ownership

DiaMedica Therapeutics Inc. Director James T. Parsons acquired 40,739 stock options and reported beneficial ownership of 75,854 common shares, signaling increased alignment with shareholder interests.

Summary

• James T. Parsons, a Director of DiaMedica Therapeutics Inc. (DMAC), reported changes in his beneficial ownership.
• On June 1, 2025, Mr. Parsons acquired 40,739 stock options with an exercise price of $4.11 per share.
• These stock options are exercisable as of June 1, 2025, and vest in four nearly equal quarterly installments over one year, with an expiration date of May 31, 2035.
• Following the reported transactions, Mr. Parsons directly beneficially owns 75,854 voting common shares.
• This beneficial ownership includes 3,850 voting common shares issuable upon settlement of deferred share units and 69,754 shares issuable upon vesting and settlement of deferred stock units granted under the company's incentive plans.
• Additionally, Mr. Parsons directly beneficially owns 40,739 derivative securities in the form of stock options.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director generally indicates confidence in the company's future and aligns management's interests with shareholders, which is a positive signal.

Positives

• Director James T. Parsons acquired 40,739 stock options, indicating a potential increase in his vested interest and alignment with the company's future performance.
• The acquisition of options by a director can be viewed as a positive signal of confidence in the company's prospects.
• The total beneficial ownership of 75,854 common shares, including deferred units, further strengthens the director's stake in the company.

Future Outlook

The acquired stock options will vest in four nearly equal quarterly installments over one year, indicating a future vesting schedule for the director's equity compensation.

Stakeholder Impact

• Shareholders: The director's increased equity stake through stock options and beneficial ownership aligns his interests more closely with those of the shareholders, potentially fostering better long-term decision-making.

Next Steps

• The acquired stock options will vest in four nearly equal quarterly installments over one year.

Key Dates

Keywords

DiaMedica Therapeutics, DMAC, Form 4, insider transaction, stock options, beneficial ownership, director, equity compensation